ArticleVaccine2010
Targeting the tumor microenvironment with anti-neu/anti-CD40 conjugated nanoparticles for the induction of antitumor immune responses.
Article in Vaccine, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 49 citations in OpenAlex.
- Antibody-conjugated polymer nanoparticles for brain cancer.Drug delivery and translational research · 2025Review
- PRIMERS: Polydopamine Radioimmunotherapy with Image-Guided Monitoring and Enhanced Release System.Pharmaceutics · 2024Article
- Emerging biomaterials for tumor immunotherapy.Biomaterials research · 2023Review
- Antibody-conjugated nanoparticles for target-specific drug delivery of chemotherapeutics.Beilstein journal of nanotechnology · 2023Review
- Nanotechnology-enabled immunoengineering approaches to advance therapeutic applications.Nano convergence · 2022Review
- Nanoparticle-based immunotherapy of pancreatic cancer.Frontiers in molecular biosciences · 2022Review
- Nanomedicine for Immunotherapy Targeting Hematological Malignancies: Current Approaches and Perspective.Nanomaterials (Basel, Switzerland) · 2021Review
- DR-5 and DLL-4 mAb Functionalized SLNs of Gamma-Secretase Inhibitors- An Approach for TNBC Treatment.Advanced pharmaceutical bulletin · 2021Review
- The application of nanoparticles in cancer immunotherapy: Targeting tumor microenvironment.Bioactive materials · 2021Review
- Nanoparticle-Based Therapies for Turning Cold Tumors Hot: How to Treat an Immunosuppressive Tumor Microenvironment.Frontiers in bioengineering and biotechnology · 2021Review
- Strategies for Precise Engineering and Conjugation of Antibody Targeted-nanoparticles for Cancer Therapy.Current medical science · 2020Review
- Nanoparticles as Smart Carriers for Enhanced Cancer Immunotherapy.Frontiers in chemistry · 2020Review
- Biomimetic Nanoparticle Vaccines for Cancer Therapy.Advanced biosystems · 2019Article
- Exploring the Immunomodulatory Moonlighting Activities of Acute Phase Proteins for Tolerogenic Dendritic Cell Generation.Frontiers in immunology · 2018Review
- Tolerance through Education: How Tolerogenic Dendritic Cells Shape Immunity.Frontiers in immunology · 2017Review
- In vivo stepwise immunomodulation using chitosan nanoparticles as a platform nanotechnology for cancer immunotherapy.Scientific reports · 2016Article
- Nanoparticle Drug Delivery Systems Designed to Improve Cancer Vaccines and Immunotherapy.Vaccines · 2015Review
- Overview of the role of nanotechnological innovations in the detection and treatment of solid tumors.International journal of nanomedicine · 2014Review
- Targeting Dendritic Cells in vivo for Cancer Therapy.Frontiers in immunology · 2012Article
- Nanovectorized radiotherapy: a new strategy to induce anti-tumor immunity.Frontiers in oncology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Clinical and preclinical data indicate that immunotherapeutic interventions could induce immune responses capable of controlling or retard the tumor growth. However, immunotherapies need to be further optimized. We hypothesized that a more effective strategy for tumor eradication is to directly target the tumor microenvironment in order to generate a proinflammatory response and induce a localized antitumor immune response capable of eliminating the tumor cells. Nanoparticles have been proven to be an effective delivery system. In these studies we evaluated conjugated anti-RNEU and anti-CD40 antibodies onto PLA-(poly dl-lactic acid)-biodegradable nanoparticles (PLA-NP) for the induction of antitumor immune responses. The anti-neu/anti-CD40-NP were functional in vitro recognizing RNEU(+) tumors and activating dendritic cells. The delivery of anti-neu/anti-CD40-NP but not anti-neu-NP or anti-CD40-NP induced an antitumor response resulting in complete tumor elimination and generation of protective memory responses. The anti-neu/anti-CD40-NP specifically activated an antitumor response against RNEU(+) tumors but not against RNEU(-) tumors. The antitumor immune responses correlate with the induction of a Th1-proinflammatory response, reduction in the number of Tregs within the tumor and activation of a specific cytotoxic response. These results indicate that anti-neu/anti-CD40-NP with immunomodulatory properties are safe and can be used effectively as cancer vaccines strategy for the specific induction of antitumor immune responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.